ATE466572T1 - Verfahren zur hemmung der gefässpermeabilität und apoptose - Google Patents
Verfahren zur hemmung der gefässpermeabilität und apoptoseInfo
- Publication number
- ATE466572T1 ATE466572T1 AT04776717T AT04776717T ATE466572T1 AT E466572 T1 ATE466572 T1 AT E466572T1 AT 04776717 T AT04776717 T AT 04776717T AT 04776717 T AT04776717 T AT 04776717T AT E466572 T1 ATE466572 T1 AT E466572T1
- Authority
- AT
- Austria
- Prior art keywords
- sphingosine
- vascular endothelial
- vascular permeability
- apoptosis
- receptor agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48223403P | 2003-06-24 | 2003-06-24 | |
PCT/US2004/019420 WO2005002559A2 (en) | 2003-06-24 | 2004-06-18 | Methods of inhibiting vascular permeability and apoptosis |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE466572T1 true ATE466572T1 (de) | 2010-05-15 |
Family
ID=33563841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04776717T ATE466572T1 (de) | 2003-06-24 | 2004-06-18 | Verfahren zur hemmung der gefässpermeabilität und apoptose |
Country Status (14)
Country | Link |
---|---|
US (3) | US7838562B2 (de) |
EP (1) | EP1643983B1 (de) |
JP (2) | JP2007523858A (de) |
CN (2) | CN100431534C (de) |
AT (1) | ATE466572T1 (de) |
AU (1) | AU2004253473B2 (de) |
BR (1) | BRPI0411831A (de) |
CA (3) | CA2529318C (de) |
DE (1) | DE602004027045D1 (de) |
ES (1) | ES2342396T3 (de) |
MX (1) | MXPA05014216A (de) |
PL (1) | PL1643983T3 (de) |
PT (1) | PT1643983E (de) |
WO (1) | WO2005002559A2 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003233119A1 (en) | 2002-05-08 | 2003-11-11 | Neuronova Ab | Modulation of neural stem cells with s1p or lpa receptor agonists |
GB0329498D0 (en) * | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
JP2008528450A (ja) * | 2005-01-21 | 2008-07-31 | メドベット サイエンス ピーティーワイ. リミティッド | 細胞損傷の治療法 |
KR100773765B1 (ko) | 2005-11-24 | 2007-11-12 | 재단법인서울대학교산학협력재단 | 개선된 스핑고신 유사체의 제조 방법 |
EP2086514A2 (de) * | 2006-09-26 | 2009-08-12 | Novartis Ag | Pharmazeutische zusammensetzungen mit einem s1p-modulator |
EP1905434A1 (de) * | 2006-09-26 | 2008-04-02 | Novartis AG | Organische S1P Rezeptor Agonist Verbindungen und ihre therapeutische Verwendung |
JP2010510314A (ja) | 2006-11-22 | 2010-04-02 | シーサイド セラピューティクス,エルエルシー | 精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法 |
KR101710845B1 (ko) | 2007-10-12 | 2017-02-27 | 노파르티스 아게 | 스핑고신 1 포스페이트 (s1p) 수용체 조절제를 포함하는 조성물 |
CN102464590B (zh) * | 2010-11-18 | 2013-10-23 | 中国科学院上海药物研究所 | 一类免疫调节剂及其制备方法和用途 |
ES2388273B1 (es) * | 2011-03-16 | 2013-10-01 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada |
AU2013240139B2 (en) | 2012-03-26 | 2017-02-23 | Arroyo Biosciences L.L.C. | Novel sphingosine 1-phosphate receptor antagonists |
WO2013181488A2 (en) * | 2012-06-01 | 2013-12-05 | The Ohio State University Research Foundation | Inhibition of leukemic stem cells by pp2a activating agents |
WO2014043334A1 (en) * | 2012-09-12 | 2014-03-20 | Oklahoma Medical Research Foundation | Modulation of podoplanin mediated platelet activation |
JP6294872B2 (ja) * | 2013-04-26 | 2018-03-14 | 国立大学法人京都大学 | 脳動脈瘤の形成および/または増大の抑制若しくは縮小用医薬組成物 |
WO2016035769A1 (ja) * | 2014-09-01 | 2016-03-10 | パスロジ株式会社 | ユーザ認証方法及びこれを実現するためのシステム |
WO2016115092A1 (en) * | 2015-01-12 | 2016-07-21 | La Jolla Institute For Allergy And Immunology | Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever |
US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
CN105395530A (zh) * | 2015-11-27 | 2016-03-16 | 天津医科大学总医院 | 芬戈莫德的新用途 |
CN105640928A (zh) * | 2016-02-26 | 2016-06-08 | 南京医科大学 | Fty720在制备预防与治疗缺血性脑卒药物中的应用 |
CN108939074B (zh) * | 2017-05-22 | 2022-06-10 | 北京蔚蓝之源医药科技有限公司 | 治疗再生障碍性贫血的方法和药物组合物 |
EP3747471A4 (de) | 2018-02-02 | 2021-10-27 | Kyoto University | Arzneimittel zur vorbeugung oder behandlung von augenerkrankungen, die mit erhöhter intraokularer neovaskularisation und / oder intraokularer gefässpermeabilität einhergehen |
EP3677259A1 (de) * | 2019-01-07 | 2020-07-08 | Mosaiques Diagnostics And Therapeutics AG | Verwendung von arachidonyl-trifluormethyl-keton |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0711168A4 (de) * | 1993-07-23 | 1998-04-01 | Lxr Biotechnology Inc | Verfahren zur behandlung vpn apoptose und damit verbundenen zustaenden |
US5948820A (en) * | 1994-08-22 | 1999-09-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzene compound and pharmaceutical use thereof |
US6476004B1 (en) * | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
WO1998009523A1 (en) * | 1996-09-05 | 1998-03-12 | Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
JPH11246434A (ja) * | 1998-02-25 | 1999-09-14 | Sumitomo Pharmaceut Co Ltd | baxの低下及び/又はbcl−2の増加誘導剤 |
JP2002505868A (ja) * | 1998-03-09 | 2002-02-26 | スミスクライン・ビーチャム・コーポレイション | ヒトEDG−1cポリヌクレオチドおよびポリペプチドおよびその使用法 |
JP4627356B2 (ja) * | 1999-06-30 | 2011-02-09 | 松森 昭 | ウイルス性心筋炎の予防または治療薬剤 |
CZ20031910A3 (cs) * | 2000-12-11 | 2003-12-17 | Tularik Inc. | Sloučenina s antagonistickými účinky na CXCR3 a farmaceutický postředek |
US6471980B2 (en) * | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
JPWO2003014727A1 (ja) * | 2001-08-08 | 2004-11-25 | 中外製薬株式会社 | 心疾患治療剤 |
US20040058894A1 (en) * | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
WO2003061567A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
GB0217152D0 (en) * | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
-
2004
- 2004-06-18 WO PCT/US2004/019420 patent/WO2005002559A2/en active Application Filing
- 2004-06-18 US US10/562,305 patent/US7838562B2/en not_active Expired - Fee Related
- 2004-06-18 ES ES04776717T patent/ES2342396T3/es not_active Expired - Lifetime
- 2004-06-18 BR BRPI0411831-6A patent/BRPI0411831A/pt not_active IP Right Cessation
- 2004-06-18 DE DE602004027045T patent/DE602004027045D1/de not_active Expired - Lifetime
- 2004-06-18 CA CA2529318A patent/CA2529318C/en not_active Expired - Fee Related
- 2004-06-18 CN CNB2004800175481A patent/CN100431534C/zh not_active Expired - Fee Related
- 2004-06-18 JP JP2006517361A patent/JP2007523858A/ja not_active Withdrawn
- 2004-06-18 PT PT04776717T patent/PT1643983E/pt unknown
- 2004-06-18 CA CA2778126A patent/CA2778126A1/en not_active Abandoned
- 2004-06-18 PL PL04776717T patent/PL1643983T3/pl unknown
- 2004-06-18 AU AU2004253473A patent/AU2004253473B2/en not_active Ceased
- 2004-06-18 EP EP04776717A patent/EP1643983B1/de not_active Expired - Lifetime
- 2004-06-18 AT AT04776717T patent/ATE466572T1/de active
- 2004-06-18 MX MXPA05014216A patent/MXPA05014216A/es active IP Right Grant
- 2004-06-18 CA CA2778309A patent/CA2778309C/en not_active Expired - Fee Related
- 2004-06-18 CN CN200810212366A patent/CN101518524A/zh active Pending
-
2010
- 2010-09-30 US US12/894,783 patent/US9101575B2/en not_active Expired - Fee Related
-
2014
- 2014-01-07 JP JP2014001034A patent/JP2014088421A/ja active Pending
-
2015
- 2015-06-18 US US14/743,352 patent/US20150283154A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2014088421A (ja) | 2014-05-15 |
JP2007523858A (ja) | 2007-08-23 |
CA2778126A1 (en) | 2005-01-13 |
WO2005002559A3 (en) | 2005-04-14 |
WO2005002559A2 (en) | 2005-01-13 |
ES2342396T3 (es) | 2010-07-06 |
US20150283154A1 (en) | 2015-10-08 |
AU2004253473B2 (en) | 2010-03-04 |
US20110015159A1 (en) | 2011-01-20 |
CA2529318A1 (en) | 2005-01-13 |
US7838562B2 (en) | 2010-11-23 |
US20080039530A1 (en) | 2008-02-14 |
PT1643983E (pt) | 2010-06-18 |
CN100431534C (zh) | 2008-11-12 |
CA2778309A1 (en) | 2005-01-13 |
BRPI0411831A (pt) | 2006-08-08 |
AU2004253473A1 (en) | 2005-01-13 |
US9101575B2 (en) | 2015-08-11 |
CN101518524A (zh) | 2009-09-02 |
MXPA05014216A (es) | 2006-03-13 |
EP1643983A2 (de) | 2006-04-12 |
EP1643983B1 (de) | 2010-05-05 |
CA2529318C (en) | 2013-09-17 |
CN1826104A (zh) | 2006-08-30 |
PL1643983T3 (pl) | 2010-10-29 |
DE602004027045D1 (de) | 2010-06-17 |
CA2778309C (en) | 2014-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE466572T1 (de) | Verfahren zur hemmung der gefässpermeabilität und apoptose | |
AR123240A2 (es) | SAL DICLORHÍDRICA O DIBENCENSULFÓNICA DE 2-FLUORO-N-METIL-4-[7-(QUINOLIN-6-ILMETIL)IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-IL]BENZAMIDA, O HIDRATOS O SOLVATOS DE LAS MISMAS; COMPOSICIÓN; MÉTODOS PARA INHIBIR LA ACTIVIDAD DE UNA TIROSINA QUINASA RECEPTORA, LA VÍA DE SEÑALIZACIÓN DE QUINASA HGF / c-MET EN CÉLULAS, LA ACTIVIDAD PROLIFERATIVA DE CÉLULAS, EL CRECIMIENTO TUMORAL EN PACIENTES, LA METÁSTASIS TUMORAL EN UN PACIENTE; MÉTODO PARA TRATAR UNA ENFERMEDAD ASOCIADA CON LA DESREGULACIÓN DE LA VÍA DE SEÑALIZACIÓN DE HGF / c-MET EN PACIENTES, CÁNCER EN PACIENTES; PROCESO PARA PREPARAR DICHOS HIDRATOS Y DICHAS SALES; Y COMPUESTOS RELACIONADOS | |
DE602006018354D1 (de) | Verfahren zur behandlung von abnormalem zellwachstum | |
NO20083918L (no) | Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser | |
ATE554725T1 (de) | Chirurgische artikel zur behandlung von beckenerkrankungen | |
ATE530142T1 (de) | Chirurgische artikel zur behandlung von beckenerkrankungen | |
BRPI0716069A2 (pt) | composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio | |
DE602004028286D1 (de) | Verwendung von sphingosin-1-phosphat (s1p) rezeptor-agonisten zur behandlung von degenerativen gehirnerkrankungen | |
EA200970447A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
ATE447593T1 (de) | Niedrigviskose uretdiongruppenhaltige polyadditionsverbindungen, verfahren zur herstellung und verwendung | |
EA201000130A1 (ru) | Бициклические гетероарильные соединения и их применение в качестве ингибиторов киназы | |
TW200634006A (en) | Tetrahydroquinoline analogues as muscarinic agonists | |
UA111933C2 (uk) | Піролопіридини як інгібітори кінази | |
ATE530558T1 (de) | Verfahren und verbindungen zur herstellung von natriumglucose-co-transporter-2-hemmern | |
HK1113569A1 (en) | Pyrazolo | |
NZ594177A (en) | Novel benzodiazepine derivatives | |
ATE455534T1 (de) | Verwendung einer hydrophilen matrix mit einem polyacrylsäurederivat, einem celluloseether und einem sprengmittel zur herstellung eines medikaments zur behandlung von erkrankungen der weiblichen genitalorgane | |
ATE480615T1 (de) | Verfahren zur proliferation von stammzellen | |
DE602005012481D1 (de) | 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck | |
ATE547134T1 (de) | Dentalimplantat und verfahren zu dessen herstellung | |
MX2011007567A (es) | Metodos para la inhibicion de la neurodegeneracion. | |
ATE439831T1 (de) | Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung | |
DE602005020135D1 (de) | Verfahren zur veränderung der alkaloidzusammensetzung von mohnpflanzen | |
RU2014124430A (ru) | Средство для лечения фиброза кишечника | |
ATE555131T1 (de) | Verfahren zur behandlung von erkrankungen mit knochenabbau unter verwendung eines gm-csf- antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1643983 Country of ref document: EP |